Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021

Rhea-AI Summary

Plus Therapeutics (Nasdaq: PSTV) will report its fourth quarter and full year 2020 financial results on February 22, 2021, after market close. A conference call will follow at 5:00 PM ET for a discussion of the results and corporate update. The company focuses on developing targeted treatments for rare cancers utilizing nanotechnology to enhance drug delivery and efficacy. Interested parties can access a live webcast and subsequent replay on their investor relations website.

Positive

• Upcoming financial results announcement on February 22, 2021, indicating ongoing corporate activity.

Negative

• None.

AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company will report fourth quarter and full year 2020 financial results on Monday, February 22, 2021, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.

A live webcast will be available at ir.plustherapeutics.com/events

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:	877-402-3914
International dial-in:	631-865-5294
Conference ID:	6206747
Conference Call Name:	Plus Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call

Following the live call, a replay will be available on the Company’s website under the 'Investor Relations' section. The webcast will be available on the Company’s website for 90 days following the live call.

About Plus Therapeutics, Inc.

Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company’s potential to develop drug candidates currently in its product pipeline; and the Company’s potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
Peter.Vozzo@westwicke.com

Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
Terri.Clevenger@westwicke.com

FAQ

When will Plus Therapeutics report its financial results for Q4 and full year 2020?

Plus Therapeutics will report its financial results on February 22, 2021, after market close.

What time is the Plus Therapeutics conference call?

The conference call will take place at 5:00 PM Eastern Time on February 22, 2021.

How can I access the Plus Therapeutics financial results webcast?

The webcast can be accessed through the investor relations section of Plus Therapeutics' website.

What is the focus of Plus Therapeutics' drug development?

Plus Therapeutics focuses on developing novel, targeted therapies for rare and difficult to treat cancers using nanotechnology.